Breast Cancer Clinical Trial
— chemobrainOfficial title:
Can Exercise Improve Cancer Associated Cognitive Dysfunction?
| Verified date | June 2016 |
| Source | University of British Columbia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Health Canada |
| Study type | Interventional |
Following chemotherapy, some breast cancer survivors report alterations in their ability to
remember, concentrate, or think, which can have significant emotional, psychological, and
economic impact on their lives. Survivors have also reported feeling frustrated by the
response of the medical community, who either may not acknowledge their symptoms or have no
treatment options to suggest. Exercise may be a promising treatment, as improvements in
cognitive function with exercise have been demonstrated in older adults and other clinical
populations.
The investigators will recruit women who have completed chemotherapy for breast cancer
(within the past 2 years) and report cognitive changes. Women will be randomly assigned to
either a 24-week aerobic exercise intervention or delayed exercise control (offered the same
exercise program following the study). At the start and end of the study the investigators
will measure: i) performance on four standard neuropsychological tests that measure working
memory, learning, and problem solving; ii) a questionnaire on cognitive function and its
impact on quality of life; iii) functional magnetic resonance imaging (fMRI) during two of
the standard neuropsychological tests which provides information on how the brain is working
during the tests.
To knowledge of the investigators this is the first study to examine the effect of an
exercise intervention on cognitive function in breast cancer survivors. In addition, the use
of fMRI imaging is a new way to approach this research question, and may be more sensitive
to change than traditional measures of cognitive function.
| Status | Completed |
| Enrollment | 31 |
| Est. completion date | June 2015 |
| Est. primary completion date | February 2014 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 40 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Women - Completed chemotherapy within past 2 years - completed for at least 3 months - Self report cognitive dysfunction following chemotherapy - Stage I-IIIA breast cancer - Physically able to undertake moderate to vigorous physical activity program Exclusion Criteria: - Self report > 90min/week of moderate physical activity (last 6 months) - Mini-mental status exam score < 23 - Co-morbid conditions that may alter cognitive testing results (i.e., a clinically diagnosed major depression, anxiety disorder, or other psychiatric condition, meeting DSM IV criteria) - History of substance abuse - Other neurological disorder (i.e., head injury, epilepsy, tumour, neurodegenerative disease) - Ruled ineligible for MRI scanning (i.e., metal implants) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Canada | University of British Columbia | Vancouver | British Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| University of British Columbia | Canadian Breast Cancer Foundation |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Stroop Test | Tests response inhibition, measure number of correct vs incorrect responses | Change from baseline at 6 months | No |
| Secondary | FACT-Cog | Self-reported cognitive function and quality of life | Change from baseline at 6 months | No |
| Secondary | fMRI analyses | regions of interest analysis, whole brain patterns of change | Change from baseline at 6 months | No |
| Secondary | Graded exercise test | Change from baseline at 6 months | No | |
| Secondary | Hopkins Verbal Learning Test | Verbal Learning, measure number of recalled and recognized words | Change from baseline at 6 months | No |
| Secondary | Trail Making A & B | Visual Conceptual and Visuomotor Tracking, measure time taken to complete | Change from baseline at 6 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |